Arjan BoltjesImportant work, the #ITCC #SIOPEN #BEACON #neuroblastoma #trial
https://ascopubs.org/doi/10.1200/JCO.23.00458
In this trial Moreno et al. assessed possible added effects of #antiangiogenic agent #bevacizumab to #temozolomide treatment plus or minus #irinotecan or #topotecan for children with relapsed and refractory neuroblastoma.
Perhaps some early effects, but after 5-6 years rather depressing survival graphs, if I'm very honest.